Author:
Shaw Alice T,Kim Tae Min,Crinò Lucio,Gridelli Cesare,Kiura Katsuyuki,Liu Geoffrey,Novello Silvia,Bearz Alessandra,Gautschi Oliver,Mok Tony,Nishio Makoto,Scagliotti Giorgio,Spigel David R,Deudon Stéphanie,Zheng Cheng,Pantano Serafino,Urban Patrick,Massacesi Cristian,Viraswami-Appanna Kalyanee,Felip Enriqueta
Reference31 articles.
1. Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in rearrangement-positive lung cancer;Iwama;Onco Targets Ther,2014
2. The potential for crizotinib in non-small cell lung cancer: a perspective review;Bang;Ther Adv Med Oncol,2011
3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010
4. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012
5. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial;Shaw;Lancet Oncol,2016
Cited by
465 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献